Prothena Corp. (PRTA) – Company Press Releases
-
Prothena Announces Review on Birtamimab Mechanism of Action and Pharmacological Characteristics Published in Leukemia & Lymphoma
-
Prothena to Participate in Upcoming Healthcare Conferences
-
Prothena Appoints David Ford to Newly Created Chief People Officer Position
-
Prothena Announces Appointment of Daniel G. Welch as Director and Chair Designate
-
Prothena Reports Fourth Quarter and Full Year 2023 Financial Results, and Provides Financial Guidance and Business Highlights
-
Prothena to Report Fourth Quarter and Full Year 2023 Financial Results on February 15, 2024
-
Prothena Provides Updates on PRX012, PRX123, Birtamimab and Portfolio Programs
-
Prothena Reports Third Quarter 2023 Financial Results and Business Highlights
-
Prothena to Report Third Quarter 2023 Financial Results on November 2
-
Prothena to Participate in Upcoming Healthcare Conferences
-
Prothena Reports Second Quarter 2023 Financial Results and Business Highlights
-
Prothena to Report Second Quarter 2023 Financial Results on August 3
-
Prothena Presents New Research in the Treatment of Alzheimer’s Disease at Alzheimer’s Association International Conference® 2023 (AAIC®)
-
Prothena to Present New Data from Alzheimer’s Disease Programs at Alzheimer’s Association International Conference® 2023 (AAIC®)
-
Prothena Announces Bristol Myers Squibb Opt-in for Worldwide Rights of PRX005, a Novel Anti-MTBR-Tau Antibody
-
Prothena Announces Phase 3 VITAL Clinical Trial Results Published in Blood Showing Survival Benefit in Patients with Mayo Stage IV AL Amyloidosis Treated with Birtamimab
-
Prothena to Participate in Jefferies 2023 Healthcare Conference
-
Prothena Announces Appointment of Billy Dunn, M.D., to its Board of Directors
-
Prothena Reports First Quarter 2023 Financial Results and Business Highlights
-
Prothena to Report First Quarter 2023 Financial Results on May 4
-
Prothena to Participate in 2023 Bank of America Healthcare Conference
-
Walgreens and Prothena Partner to Increase Access and Enrollment in Alzheimer’s Disease Clinical Trial
-
Prothena Presents New Preclinical Data Supporting Best-in-Class Profile of PRX012, a Next-Generation Anti-Amyloid Beta Antibody, at AD/PD 2023
-
Prothena to Participate in Stifel 2023 Virtual CNS Days
-
Prothena to Highlight Next Generation Treatments for Alzheimer’s and Parkinson’s Disease at the AD/PD 2023 Meeting
-
Prothena Reports Fourth Quarter and Full Year 2022 Financial Results, and Provides Financial Guidance and Business Highlights
-
Prothena to Report Fourth Quarter and Full Year 2022 Financial Results on February 23, 2023
-
Prothena Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Prothena Reports Topline Phase 1 Single Ascending Dose Study Results of PRX005, a Novel Anti-MTBR-Tau Antibody for the Potential Treatment of Alzheimer’s Disease
-
Prothena Announces Pricing of Public Offering of 3,250,000 Ordinary Shares
-
Prothena Announces Proposed Public Offering of Ordinary Shares
-
Prothena Presents Data Demonstrating Consistent Survival Benefit Observed with Birtamimab in Mayo Stage IV AL Amyloidosis Patients in Phase 3 VITAL Study at ASH 2022
-
Prothena Announces Achievement of $40 Million Clinical Milestone Payment from Novo Nordisk for PRX004/NNC6019 Under Investigation for the Treatment of ATTR Cardiomyopathy
-
Prothena Reports Third Quarter 2022 Financial Results and Business Highlights
-
Prothena to Present Data on Survival Benefit Observed in Completed Phase 3 Study of Drug Candidate Birtamimab in Patients with Mayo Stage IV AL Amyloidosis at the ASH 2022 Meeting
-
Prothena to Report Third Quarter 2022 Financial Results on November 3rd
-
Prothena to Report Third Quarter 2022 Financial Results on November 3rd
-
Prothena to Participate in Upcoming Healthcare Conferences
-
Prothena to Participate in Upcoming Healthcare Conferences
-
Prothena Announces Appointment of Biotechnology Industry Leader Helen S. Kim to its Board of Directors
-
Prothena Announces Appointment of Biotechnology Industry Leader Helen S. Kim to its Board of Directors
-
Prothena Reports Second Quarter 2022 Financial Results and Business Highlights
-
Prothena Reports Second Quarter 2022 Financial Results and Business Highlights
-
Prothena Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Prothena Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Prothena to Report Second Quarter 2022 Financial Results on August 8th
-
Prothena to Report Second Quarter 2022 Financial Results on August 8th
-
Prothena Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Prothena Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Prothena to Participate in Jefferies Healthcare Conference
Back to PRTA Stock Lookup
